Evidence map›Paper›PMID 41796056›Full record

ReviewClinical and translational science2026

Review of Existing Approaches and Potential Role of Pharmacometrics in the Interpretation of Prognostic Circulating Serum Biomarkers in Advanced NSCLC.

Francis Williams Ojara, Yomna M Nassar, Kimberly Geiger, Madele van Dyk, Stefan Holdenrieder, Markus Joerger, Charlotte Kloft

Abstract readReview
In one paragraph

Review in Clinical and translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Francis Williams OjaraDepartment of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universität Berlin, Berlin, Germany.ORCID 0000-0002-6425-6828
Yomna M NassarDepartment of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universität Berlin, Berlin, Germany.ORCID 0000-0003-0507-7130
Kimberly GeigerInstitute of Laboratory Medicine, Munich Biomarker Research Center, TUM University Hospital-German Heart Center, Munich, Germany.
Madele van DykDepartment of Clinical Pharmacology, The Basil Hetzel Institute for Translational Health Research, The Queen Elizabeth Hospital, Woodville South, South Australia, Australia.ORCID 0000-0001-8721-6370
Stefan HoldenriederInstitute of Laboratory Medicine, Munich Biomarker Research Center, TUM University Hospital-German Heart Center, Munich, Germany.ORCID 0000-0001-8893-1253
Markus JoergerDepartment of Medical Oncology and Haematology, Cantonal Hospital, St. Gallen, Switzerland.ORCID 0000-0001-6602-6287
Charlotte KloftDepartment of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universität Berlin, Berlin, Germany.ORCID 0000-0001-9344-8514

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Circulating serum biomarkers have prognostic value in patients with advanced NSCLC, yet their potential still remains underappreciated at present. This review discusses classical approaches of biomarker data analysis, highlighting gaps, and summarizing current methodologies to evaluate the relationship between serum biomarkers and clinical outcome in advanced NSCLC. Showcased for serum biomarker data exploitation of a phase III study in advanced NSCLC patients, this review also promotes and offers perspectives on how to analyze and interpret longitudinal biomarker data using pharmacometric approaches for potential implementation into clinical practice.

Indexed as

Biomarkers, TumorCarcinoma, Non-Small-Cell LungLung NeoplasmsClinical Trials, Phase III as TopicHumansPrognosisBiomarkers, Tumoradvanced non‐small cell lung cancerbiomarkermodelingNSCLCpharmacometricsprognosisstatistical methods

Identifiers

PMID41796056
PMCPMC12967872

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.